Suppression	O
of	O
lung	B-Cancer
tumor	I-Cancer
growth	O
and	O
metastasis	O
in	O
mice	O
by	O
adeno	O
-	O
associated	O
virus	O
-	O
mediated	O
expression	O
of	O
vasostatin	O
.	O

PURPOSE	O
:	O
Angiogenesis	O
inhibitors	O
have	O
strong	O
therapeutic	O
potential	O
as	O
antitumor	B-Cancer
agents	O
in	O
suppressing	O
tumor	B-Cancer
growth	O
and	O
metastatic	O
progression	O
.	O

Vasostatin	O
,	O
the	O
N	O
-	O
terminal	O
domain	O
of	O
calreticulin	O
,	O
is	O
a	O
potent	O
angiogenesis	O
inhibitor	O
.	O

In	O
this	O
study	O
,	O
we	O
determined	O
the	O
effectiveness	O
of	O
vasostatin	O
delivered	O
by	O
recombinant	O
pseudotype	O
adeno	O
-	O
associated	O
virus	O
2	O
/	O
5	O
(	O
rAAV2	O
/	O
5	O
-	O
VAS	O
)	O
as	O
a	O
gene	O
therapy	O
approach	O
for	O
lung	B-Cancer
cancer	I-Cancer
treatment	O
.	O

EXPERIMENTAL	O
DESIGN	O
:	O
We	O
used	O
rAAV2	O
/	O
5	O
to	O
deliver	O
vasostatin	O
intratumorally	B-Cancer
or	O
systemically	O
in	O
different	O
mouse	O
lung	B-Cancer
tumor	I-Cancer
models	O
-	O
-	O
subcutaneous	B-Cancer
,	I-Cancer
orthotopic	I-Cancer
xenograft	I-Cancer
,	O
and	O
spontaneous	O
metastasis	O
lung	B-Cancer
tumor	I-Cancer
models	O
.	O

The	O
therapeutic	O
efficacy	O
of	O
rAAV2	O
/	O
5	O
-	O
VAS	O
was	O
determined	O
by	O
monitoring	O
tumor	B-Cancer
volume	O
,	O
survival	O
rate	O
,	O
and	O
degree	O
of	O
neovascularization	O
after	O
treatment	O
in	O
these	O
models	O
.	O

RESULTS	O
:	O
Mice	O
bearing	O
subcutaneous	B-Cancer
tumor	I-Cancer
of	O
rAAV2	O
/	O
5	O
-	O
VAS	O
pretreated	O
Lewis	B-Cell
lung	I-Cell
carcinoma	I-Cell
cells	I-Cell
showed	O
>	O
50	O
%	O
reduction	O
in	O
primary	B-Cancer
tumor	I-Cancer
volume	O
and	O
reduced	O
spontaneous	O
pulmonary	B-Cancer
metastases	I-Cancer
.	O

The	O
tumor	B-Cancer
-	O
suppressive	O
action	O
of	O
rAAV2	O
/	O
5	O
-	O
VAS	O
in	O
subcutaneous	B-Cancer
human	I-Cancer
lung	I-Cancer
tumor	I-Cancer
A549	I-Cancer
xenograft	I-Cancer
correlated	O
with	O
a	O
reduced	O
number	O
of	O
capillary	B-Tissue
vessels	I-Tissue
in	O
tumors	B-Cancer
.	O

In	O
the	O
orthotopic	O
xenograft	B-Cancer
model	O
,	O
rAAV2	O
/	O
5	O
-	O
VAS	O
suppressed	O
metastasis	O
of	O
A549	B-Cancer
tumors	I-Cancer
to	O
mediastinal	O
lymph	B-Multi-tissue_structure
nodes	I-Multi-tissue_structure
and	O
contralateral	O
lung	B-Organ
.	O

Furthermore	O
,	O
treatment	O
of	O
immunocompetent	O
mice	O
in	O
the	O
spontaneous	O
lung	B-Cancer
metastases	I-Cancer
model	O
with	O
rAAV2	O
/	O
5	O
-	O
VAS	O
after	O
primary	B-Cancer
tumor	I-Cancer
excision	O
prolonged	O
their	O
median	O
survival	O
from	O
21	O
to	O
51	O
.	O
5	O
days	O
.	O

CONCLUSION	O
:	O
Our	O
results	O
show	O
the	O
effectiveness	O
of	O
rAAV2	O
/	O
5	O
-	O
VAS	O
as	O
an	O
angiogenesis	O
inhibitor	O
in	O
suppressing	O
tumor	B-Cancer
growth	O
during	O
different	O
stages	O
of	O
tumor	B-Cancer
progression	O
,	O
validating	O
the	O
application	O
of	O
rAAV2	O
/	O
5	O
-	O
VAS	O
gene	O
therapy	O
in	O
treatment	O
against	O
lung	B-Cancer
cancer	I-Cancer
.	O

